CAJ | 학술논문

目的：探讨Rab家族结合蛋白（ RCP）在头颈鳞癌细胞及喉鳞状细胞癌（ LSCC）组织中的表达及其临床意义。方法采用Western blot法检测RCP蛋白在永生化鼻咽上皮细胞NP?69和头颈鳞癌细胞中的表达水平，采用免疫组化技术检测RCP蛋白在87例LSCC组织、18例癌旁组织及16例声带白斑中的表达水平，分析RCP表达与LSCC临床病理特征和预后的关系。结果 RCP蛋白在NP?69细胞、低淋巴结转移肿瘤细胞Tu212和Tu686、高淋巴结转移肿瘤细胞M2和M4中的表达水平依次增高，其相对表达水平分别为0．05±0．01、0．38±0．05、0．63±0．02、0．84±0．06和0．96±0．04，差异有统计学意义（P＜0．05）。 RCP蛋白在癌旁组织、声带白斑和LSCC组织中的表达水平也呈逐次增高趋势。87例LSCC组织中，RCP低表达28例（32．2％），RCP高表达59例（67．8％）。18例癌旁组织中，RCP均为低表达。16例声带白斑中，RCP均为低表达。 RCP蛋白表达水平与LSCC的T分期、临床分期、淋巴结转移和肿瘤复发有关（均P＜0．05）。 RCP高表达组和RCP低表达组LSCC患者的5年生存率分别为40．0％和75．0％，5年无瘤生存率分别为30．7％和64．0％，差异有统计学意义（P＜0．05）。单因素分析显示，饮酒、吸烟、T分期、临床分期、淋巴结转移及 RCP蛋白表达与LSCC患者术后生存有关（均P＜0．05）。多因素分析显示，RCP蛋白表达水平和淋巴结转移是影响LSCC患者预后的独立因素（均P＜0．05）。结论 RCP蛋白表达水平可能与LSCC的恶性进展有关，可能成为评估肿瘤复发、颈部淋巴结转移及患者预后的一个重要指标。
목적：탐토Rab가족결합단백（ RCP）재두경린암세포급후린상세포암（ LSCC）조직중적표체급기림상의의。방법채용Western blot법검측RCP단백재영생화비인상피세포NP?69화두경린암세포중적표체수평，채용면역조화기술검측RCP단백재87례LSCC조직、18례암방조직급16례성대백반중적표체수평，분석RCP표체여LSCC림상병리특정화예후적관계。결과 RCP단백재NP?69세포、저림파결전이종류세포Tu212화Tu686、고림파결전이종류세포M2화M4중적표체수평의차증고，기상대표체수평분별위0．05±0．01、0．38±0．05、0．63±0．02、0．84±0．06화0．96±0．04，차이유통계학의의（P＜0．05）。 RCP단백재암방조직、성대백반화LSCC조직중적표체수평야정축차증고추세。87례LSCC조직중，RCP저표체28례（32．2％），RCP고표체59례（67．8％）。18례암방조직중，RCP균위저표체。16례성대백반중，RCP균위저표체。 RCP단백표체수평여LSCC적T분기、림상분기、림파결전이화종류복발유관（균P＜0．05）。 RCP고표체조화RCP저표체조LSCC환자적5년생존솔분별위40．0％화75．0％，5년무류생존솔분별위30．7％화64．0％，차이유통계학의의（P＜0．05）。단인소분석현시，음주、흡연、T분기、림상분기、림파결전이급 RCP단백표체여LSCC환자술후생존유관（균P＜0．05）。다인소분석현시，RCP단백표체수평화림파결전이시영향LSCC환자예후적독립인소（균P＜0．05）。결론 RCP단백표체수평가능여LSCC적악성진전유관，가능성위평고종류복발、경부림파결전이급환자예후적일개중요지표。
Objective To explore the RCP protein expression and its clinicopathological significance in laryngeal squamous cell carcinoma ( LSCC ) . Methods RCP protein expression in human head and neck squamous cell carcinoma cell lines (NP?69, Tu686, Tu212, M2 and M4) was analyzed by Western blotting. Besides, its expression in 87 cases of LSCC, 18 cases of adjacent epithelial mucosa and 16 cases of vocal cord leukoplakia was detected by immunohistochemistry, and their correlation with clinicopathological parameters and patients’ outcome was analyzed. Results The NP?69, Tu212 Tu686, M2 and M4 cells showed a gradual increase in the expression of RCP protein. The average relative expression levels of RCP protein in the NP?69, Tu212, Tu686, M2 and M4 cells were 0. 05 ± 0. 01, 0. 38 ± 0. 05, 0. 63 ± 0. 02, 0. 84 ± 0. 06 and 0. 96 ± 0. 04, respectively. The same situation occurred in the adjacent mucosa, vocal cord leukoplakia and LSCC. Specifically, only 3 of 18 adjacent mucosa showed a low RCP expression (scored 0?2). Although the 16 cases of vocal cord leukoplakia had a low RCP expression, all their scores ranged from 0 to 3. While in the LSCC specimens, 59 (67. 8%) cases demonstrated a high RCP expression (scored 8?15), 18 cases showed a lower RCP expression (scored 4?7), and only 10 cases were scored 2?3. Among the 87 LSCC cases, there were 28 cases (32. 2%) of low RCP expression and 59 cases of high RCP expression. All the 18 cases of cancer?adjacent tissues and 16 cases of vocal cord leukoplakia were of low RCP expression. RCP overexpression was significantly associated with T classification, clinical staging, lymph node metastasis and recurrence (P<0. 05 for all). Survival analysis revealed that the 5?year survival rate was 40. 0% in the patients with high RCP expression and 75. 0% in the patients with low RCP expression, the tumor?free 5?year survival rate was 30. 7% and 64. 0%, respectively, both showing a significant difference between the two subgroups (P<0. 05). Univariate analysis revealed that alcohol history;smoking, T classification, clinical staging, lymph node metastasis and RCP expression were significantly associated with a poor prognosis (P<0. 05 for all). The multivariate analysis showed that only recurrence and RCP expression were independent prognostic factors affecting the prognosis for patients with LSCC (P<0. 05 for both). Conclusions Expression of RCP protein may contribute to the malignant progression of LSCC, and may become a novel marker predicting tumor recurrence, cervical lymph node metastasis and prognosis for patients with laryngeal squamous cell carcinoma.